Diablo Valley Oncology Prepared To Administer Kadcyla for Metastatic Breast Cancer Patients
New Personalized Medicine Drug Helps Breast Cancer Patients Live Longer
Pleasant Hill, CA (March 1, 2013) – Diablo Valley Oncology (DVO) physicians and staff met today with representatives from Genentech to obtain the necessary information in order to begin administering Kadcyla™ (ado-trastuzumab emtansine or T-DM1), recently approved by the US Food and Drug Administration for the treatment of people with HER2-positive metastatic breast cancer.
Antibody-drug conjugate (ADC) is a new kind of targeted cancer medicine that can attach to certain types of cancer cells and deliver chemotherapy directly to them. Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC, an aggressive form of the disease.
“Kadcyla is a drug we have all been waiting for because it is a novel type of agent that represents a completely new way to treat HER2-positive metastatic breast cancer – it is truly targeted treatment at its best, said Tiffany Svahn, MD, Medical Oncologist at DVO specializing in breast cancer. “In the Phase III clinical trial EMILIA, Kadcyla had an improved overall survival when compared with the standard regimen with fewer side effects. This represents an important step forward in the treatment of this particular type of breast cancer.”
Kadcyla is made up of the antibody, trastuzumab, and the chemotherapy, DM1, joined together using a stable linker. Kadcyla combines the mechanisms of action of both trastuzumab and DM1, and it is the first Genentech ADC approved by the FDA. Genentech has studied ADC science for more than a decade and has eight ADCs in Phase I or Phase II studies for different types of cancer.
Diablo Valley Oncology plans to work with Genentech’s patient assistance program to help those who might not be able to afford Kadcyla by qualifying to receive financial assistance or free of charge medication.
About Diablo Valley Oncology
Diablo Valley Oncology and Hematology Medical Group is home to the largest single site for cancer treatment in Contra Costa County. Their 13 physicians bring together medical oncology; hematology; urology; chemotherapy; radiation therapy; CT/MRI/PET-CT imaging; clinical research and supportive care all in one convenient location.